{
    "root": "b8f4c206-5f06-4692-819f-a40794db11bb",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": "Cisatracurium Besylate",
    "value": "20250115",
    "ingredients": [
        {
            "name": "CISATRACURIUM BESYLATE",
            "code": "80YS8O1MBS",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3721"
        },
        {
            "name": "BENZENESULFONIC ACID",
            "code": "685928Z18A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_64455"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "cisatracurium besylate injection indicated : \u2022 adjunct general anesthesia facilitate tracheal intubation adults pediatric patients 1 month 12 years age \u2022 provide skeletal muscle relaxation adults surgical procedures mechanical ventilation icu \u2022 provide skeletal muscle relaxation surgical procedures via infusion pediatric patients 2 years older . limitations cisatracurium besylate injection recommended rapid sequence endotracheal intubation due time required onset action .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "store cisatracurium besylate injection cap ferrule intact manner minimizes possibility selecting wrong product ( 2.1 ) \u2022 administer intravenously supervision experienced clinicians familiar \u2019 actions possible complications ( 2.1 ) \u2022 personnel facilities resuscitation life support , cisatracurium besylate antagonist immediately available ( 2.1 ) \u2022 peripheral nerve stimulator determine adequacy blockade ( e.g . , need additional doses ) , minimize risk overdosage underdosage , assess extent recovery blockade , potentially limit exposure toxic metabolites dose titration , facilitate rapid reversal cisatracurium besylate -induced paralysis ( 2.1 ) full prescribing information : \u2022 instructions adults , pediatric patients , geriatric patients , patients neuromuscular disease , burns , end-stage renal disease , patients undergoing coronary artery bypass graft surgery induced hypothermia ( 2.2 , 2.3 , 2.4 , 2.5 ) \u2022 continuous infusion rates ( 2.6 ) \u2022 preparation instructions ( 2.7 ) \u2022 compatibility ( 2.8 )",
        "doid_entities": [
            {
                "text": "neuromuscular disease (DOID:440)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_440"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "cisatracurium besylate injection , usp clear solution supplied follows : strength ( mg cisatracurium ) containers ndc # preservative 200 mg/20 ml ( 10 mg/ml ) single-dose vial 72485-513-10 containbenzyl alcohol discard unused portion 20 ml single-dose vials . storage refrigerate cisatracurium besylate usp 2\u00b0c 8\u00b0c ( 36\u00b0f 46\u00b0f ) carton preserve potency . protect light . freeze.upon removal refrigeration , within 21 days even re-refrigerated .",
    "adverseReactions": "\u2022 cisatracurium besylate contraindicated patients known hypersensitivity cisatracurium . severe anaphylactic cisatracurium besylate reported [ ( 5.4 ) ] .",
    "indications_original": "Cisatracurium Besylate injection is indicated:\n                      \u2022\u00a0as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age \u2022\u00a0to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the ICU \u2022\u00a0to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older.\n                     \n                     Limitations of Use\n                     \n                      Cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action.",
    "contraindications_original": "Store Cisatracurium besylate injection with the cap and ferrule intact and in a manner that minimizes the possibility of selecting the wrong product ( 2.1 ) \u2022 Administer intravenously only by or under the supervision of experienced clinicians familiar with drug\u2019s actions and possible complications ( 2.1 ) \u2022 Use only if personnel and facilities for resuscitation and life support, and a cisatracurium besylate antagonist are immediately available ( 2.1 ) \u2022\u00a0Use a peripheral nerve stimulator to determine adequacy of blockade (e.g., need for additional doses), minimize risk of overdosage or underdosage, assess extent of recovery from blockade, potentially limit exposure to toxic metabolites through dose titration, and facilitate more rapid reversal of cisatracurium besylate -induced paralysis ( 2.1 ) See the Full Prescribing Information for: \u2022\u00a0Dosage and administration instructions in adults, pediatric patients, geriatric patients, patients with neuromuscular disease, burns, end-stage renal disease, and patients undergoing coronary artery bypass graft surgery with induced hypothermia ( 2.2 , 2.3 , 2.4 , 2.5 ) \u2022\u00a0Continuous infusion rates ( 2.6 ) \u2022\u00a0Preparation instructions ( 2.7 ) \u2022\u00a0Drug compatibility ( 2.8 )",
    "warningsAndPrecautions_original": "Cisatracurium Besylate Injection, USP is a clear solution supplied as follows:\n                  \n                     \n                        \n                        \n                        \n                        \n                     \n                     \n                        \n                           \n                              Strength\n                              \n                              (mg of Cisatracurium)\n                           \n                           \n                              Containers\n                           \n                           \n                              NDC#\n                           \n                           \n                              Preservative\n                           \n                        \n                        \n                           200 mg/20 mL (10 mg/mL)\n                           Single-dose vial\n                           72485-513-10\n                           Does not containbenzyl alcohol\n                        \n                     \n                  \n                  Discard unused portion of the 20 mL single-dose vials.\n                  \n                     Storage\n                  \n                  Refrigerate cisatracurium besylate USP at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F) in the carton to preserve potency. Protect from light. DO NOT FREEZE.Upon removal from the refrigeration, use within 21 days even if re-refrigerated.",
    "adverseReactions_original": "\u2022 Cisatracurium besylate is contraindicated in patients with known hypersensitivity to cisatracurium. Severe anaphylactic reactions to cisatracurium besylate have been reported [see Warnings and Precautions (5.4)].",
    "drug": [
        {
            "name": "Cisatracurium Besylate",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3721"
        }
    ]
}